Vimpat and Learning disability - a phase IV clinical study of FDA data
Summary:
Learning disability is reported as a side effect among people who take Vimpat (lacosamide), especially for people who are male, 2-9 old, also take Keppra, and have Astrocytoma, low grade.
The phase IV clinical study analyzes which people have Learning disability when taking Vimpat. It is created by eHealthMe based on reports of 20,279 people who have side effects when taking Vimpat from the FDA, and is updated regularly.
What is Vimpat?
Vimpat has active ingredients of lacosamide. It is often used in epilepsy. eHealthMe is studying from 20,831 Vimpat users. Check the latest studies of Vimpat.
What is Learning disability?
Learning disability (difficulty in learning) is found to be associated with 152 drugs and 206 conditions by eHealthMe. Check the latest studies of Learning disability.
20,279 people reported to have side effects when taking Vimpat.
Among them, 11 people (0.05%) have Learning disability.

Among these 11 people:
What is the gender of people who have Learning disability when taking Vimpat? *
- female: 50 %
- male: 50 %
What is the age of people who have Learning disability when taking Vimpat? *
- 0-1: 0.0 %
- 2-9: 80 %
- 10-19: 20 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 0.0 %
- 50-59: 0.0 %
- 60+: 0.0 %
What are other drugs people take besides Vimpat? *
- Trileptal: 4 people, 36.36%
- Keppra: 4 people, 36.36%
- Vitamin D: 2 people, 18.18%
- Midazolam: 2 people, 18.18%
- Magnesium: 2 people, 18.18%
- Lexapro: 2 people, 18.18%
- Afinitor: 2 people, 18.18%
- Topamax: 1 person, 9.09%
- Keppra Xr: 1 person, 9.09%
What are other side effects people have besides Learning disability? *
- Hypoaesthesia (reduced sense of touch or sensation): 3 people, 27.27%
- Developmental Reading Disorder: 3 people, 27.27%
- Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 3 people, 27.27%
- Drowsiness: 3 people, 27.27%
- Weight Increased: 2 people, 18.18%
- Appetite - Increased (increased appetite is when you want to eat much more often or in larger quantities than your body requires): 2 people, 18.18%
- Dental Caries: 2 people, 18.18%
- Diarrhea: 2 people, 18.18%
- Fever: 2 people, 18.18%
- High Blood Cholesterol: 2 people, 18.18%
What are the existing conditions these people have? *
- Astrocytoma, Low Grade (low grade tumour of the brain that originate in a particular kind of glial-cells): 2 people, 18.18%
* Approximation only. Some reports may have incomplete information.
Do you take Vimpat and have Learning disability?
- Check whether Learning disability is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Vimpat:
- Vimpat (20,831 reports)
Learning disability treatments and more:
- Learning disability (7,272 reports)
How severe was Learning disability and when was it recovered:
Expand to all the drugs that have ingredients of lacosamide:
Sub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Vimpat:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Learning disability:
- Learning disability (152 drugs)
Browse all the conditions that are associated with Learning disability:
- Learning disability (206 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on lacosamide (the active ingredients of Vimpat) and Vimpat (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Broken Bone and drugs of ingredients of acyclovir - 5 seconds ago
- Rashes and drugs of ingredients of azelastine hydrochloride; fluticasone propionate - 8 seconds ago
- Doxorubicin Hydrochloride and Rash Generalised for Boys aged 10-19 - 9 seconds ago
- Doxorubicin Hydrochloride and Rash for Boys aged 10-19 - 9 seconds ago
- Doxorubicin Hydrochloride and Skin Redness Or Inflammation for Boys aged 10-19 - 10 seconds ago
- Doxorubicin Hydrochloride and Skin Rash for Boys aged 10-19 - 10 seconds ago
- Doxorubicin Hydrochloride and Skin Lesion for Boys aged 10-19 - 10 seconds ago
- Doxorubicin Hydrochloride and Rubor for Boys aged 10-19 - 10 seconds ago
- Doxorubicin Hydrochloride and Erythema for Boys aged 10-19 - 11 seconds ago
- Doxorubicin Hydrochloride and Rashes for Boys aged 10-19 - 11 seconds ago